Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)
Information source: Hallym University Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Attention Deficit Disorder With Hyperactivity; Methylphenidate; Pharmacogenetics
Intervention: norepinephrine transporter polymorphism, (Genetic)
Phase: Phase 4
Status: Completed
Sponsored by: Hallym University Medical Center
Summary
The noradrenergic system plays a known role in attentional systems and suspected causal role
in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as
a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that
norepinephrine transporter polymorphism is associated with responses and adverse effects of
OROS-methylphenidate in treatment of ADHD.
Clinical Details
Official title: Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Korean ADHD Rating scale-parent version (KARS)
Secondary outcome: Barkely side effect rating scale
Eligibility
Minimum age: 6 Years.
Maximum age: 18 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- ADHD
- Physically healthy
Exclusion Criteria:
- Neurological illness
- Concurrent additional psychiatric treatment
- < IQ 70
- Psychotic disorder
- Major mood disorder needed other psychiatric medication
- Significant suicidal ideation
- Pervasive developmental disorder
Locations and Contacts
Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea, Republic of
Additional Information
Starting date: October 2005
Last updated: October 4, 2011
|